# Obesity, Nutrition and the Multiple Sclerosis Risk in Adolescents

**Authors:** Marta Giovengo, Margherita Rosa, Claudia Mandato

PMC · DOI: 10.3390/brainsci16030283 · 2026-02-28

## TL;DR

The paper explores how obesity and diet influence the risk and progression of Multiple Sclerosis in adolescents, highlighting the role of gut health and metabolic interventions.

## Contribution

The paper establishes obesity as an independent risk factor for MS and identifies the gut–liver–brain axis as a key pathway linking diet and neuroinflammation.

## Key findings

- Obesity induces metabolic stress and epigenetic changes that promote a pro-inflammatory environment linked to MS.
- Diet-induced gut dysbiosis and bile acid modifications trigger systemic inflammation and blood–brain barrier disruption.
- The Mediterranean Diet and GLP-1 receptor agonists show promise in reducing MS risk and offering neuroprotection.

## Abstract

What are the main findings?
Multiple Sclerosis (MS) involves a distinct prodromal phase. Obesity is an independent risk factor, inducing metabolic stress and epigenetic reprogramming that establish a pro-inflammatory environment that lowers the threshold for autoimmune activation.The pathogenesis of MS involves a dysfunctional gut–liver–brain axis where diet-induced dysbiosis and secondary bile acid modification trigger systemic inflammation, leading to blood–brain barrier disruption and sustained neuroinflammation.

Multiple Sclerosis (MS) involves a distinct prodromal phase. Obesity is an independent risk factor, inducing metabolic stress and epigenetic reprogramming that establish a pro-inflammatory environment that lowers the threshold for autoimmune activation.

The pathogenesis of MS involves a dysfunctional gut–liver–brain axis where diet-induced dysbiosis and secondary bile acid modification trigger systemic inflammation, leading to blood–brain barrier disruption and sustained neuroinflammation.

What are the implications of the main findings?
The Mediterranean Diet serves as a biologically active determinant of immune regulation rather than a mere lifestyle factor, with higher adherence significantly associated with reduced MS risk and improved clinical outcomes.Metabolic interventions, including GLP-1 receptor agonists and bile acid modulation, represent promising therapeutic strategies that can provide dual benefits by managing obesity while exerting direct neuroprotective effects.

The Mediterranean Diet serves as a biologically active determinant of immune regulation rather than a mere lifestyle factor, with higher adherence significantly associated with reduced MS risk and improved clinical outcomes.

Metabolic interventions, including GLP-1 receptor agonists and bile acid modulation, represent promising therapeutic strategies that can provide dual benefits by managing obesity while exerting direct neuroprotective effects.

Multiple Sclerosis (MS) is a chronic, autoimmune neurological disease resulting from the interplay between genetic susceptibility and environmental factors. In recent decades, the rising incidence of MS, particularly pediatric-onset forms, has paralleled the global obesity pandemic. This article explores the causal link between pediatric obesity, systemic inflammation, and neuroinflammation, with a specific focus on the microbiota–gut–liver–brain axis. We analyze how nutritional habits can play a pivotal role by inducing dysbiosis, with alteration in microbiota-driven metabolites, and leaky gut related abnormalities—which may trigger blood–brain barrier (BBB) disruption and microglial activation—or by acting as a protective factor, such as through the Mediterranean Diet (MD). Furthermore, we evaluate the emerging therapeutic perspectives offered by Glucagon-Like Peptide-1 (GLP-1) agonists, which may offer dual benefits in weight management and immune modulation.

## Linked entities

- **Chemicals:** GLP-1 (PubChem CID 16133831)
- **Diseases:** Multiple Sclerosis (MONDO:0005301), obesity (MONDO:0011122)

## Full-text entities

- **Genes:** GGTLC5P (gamma-glutamyltransferase light chain 5 pseudogene) [NCBI Gene 653590] {aka GGT}, HLA-DRB1 (major histocompatibility complex, class II, DR beta 1) [NCBI Gene 3123] {aka DRB1, HLA-DR1B, HLA-DRB, SS1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971] {aka BAR, FXR, HRR-1, HRR1, PFIC5, RIP14}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, GH1 (growth hormone 1) [NCBI Gene 2688] {aka GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B}, FABP4 (fatty acid binding protein 4) [NCBI Gene 2167] {aka A-FABP, AFABP, ALBP, HEL-S-104, aP2}, RETN (resistin) [NCBI Gene 56729] {aka ADSF, FIZZ3, RENT, RETN1, RSTN, XCP1}, GGH (gamma-glutamyl hydrolase) [NCBI Gene 8836] {aka GATD10, GH}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, GPBAR1 (G protein-coupled bile acid receptor 1) [NCBI Gene 151306] {aka BG37, GPCR19, GPR131, M-BAR, TGR5}, GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}, MIR107 (microRNA 107) [NCBI Gene 406901] {aka MIRN107, miR-107}, RBP4 (retinol binding protein 4) [NCBI Gene 5950] {aka MCOPCB10, RDCCAS}, MIR155 (microRNA 155) [NCBI Gene 406947] {aka MIRN155, miRNA155, mir-155}, MIR124-3 (microRNA 124-3) [NCBI Gene 406909] {aka MIRN124-3, MIRN124A3, mir-124-3}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, HDAC9 (histone deacetylase 9) [NCBI Gene 9734] {aka HD7, HD7b, HD9, HDAC, HDAC7B, HDAC9B}
- **Diseases:** weight loss (MESH:D015431), MS (MESH:D009103), endotoxemia (MESH:D019446), visual disturbances (MESH:D014786), brain atrophy (MESH:C566985), overweight (MESH:D050177), autoimmune (MESH:D001327), Metabolic (MESH:D008659), Epstein-Barr virus infection (MESH:D020031), hepatic inflammation (MESH:D007249), gut (MESH:C536735), Pediatric (MESH:D063766), hepatobiliary diseases (MESH:D004066), metabolic and immune-mediated disorders (MESH:C567355), bile acid dysregulation (MESH:C567652), NMO (MESH:D009471), fatigue (MESH:D005221), immune dysregulation (OMIM:614878), MASLD (MESH:D008107), Obese (MESH:D009765), autoimmune neurological disease (MESH:D020274), type-2 diabetes (MESH:D003924), demyelinating diseases (MESH:D003711), experimental autoimmune encephalomyelitis (MESH:D004681), Vitamin D deficiency (MESH:D014808), injury to (MESH:D014947), respiratory infections (MESH:D012141), axonal damage (MESH:D001480), neurodegenerative disease (MESH:D019636), Sweet Death (MESH:D016463), diabetes (MESH:D003920), mitochondrial dysfunction (MESH:D028361), Neuroinflammation (MESH:D000090862), Gut Dysbiosis (MESH:D064806), Toxicity (MESH:D064420), immune dysfunction (MESH:D007154)
- **Chemicals:** glutathione (MESH:D005978), BAs (MESH:D001464), S-allyl-mercaptocysteine (MESH:C086300), BA (MESH:D001647), Fructose (MESH:D005632), sulforaphane (MESH:C016766), butyrate (MESH:D002087), glucose (MESH:D005947), SCFAs (MESH:D005232), sugars (MESH:D000073893), vitamin D (MESH:D014807), polyphenols (MESH:D059808), LPS (MESH:D008070), ESI1 (-), monounsaturated fatty acids (MESH:D005229), cortisol (MESH:D006854), dimethyl fumarate (MESH:D000069462), fat (MESH:D005223), lipid (MESH:D008055), TUDCA (MESH:C031655), UDCA (MESH:D014580), iron (MESH:D007501)
- **Species:** Brassica oleracea var. italica (asparagus broccoli, varietas) [taxon 36774], Allium sativum (garlic, species) [taxon 4682], Eggerthella (genus) [taxon 84111], Methanobrevibacter (genus) [taxon 2172], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13025375/full.md

---
Source: https://tomesphere.com/paper/PMC13025375